|
Stages I–II (n=102)
|
P53
| |
Phospho-p53
| |
Wip1
| |
Nuclear phospho-p38
| |
Cytoplasmic phospho-p38
| |
|---|
| |
Positive
|
Negative
| |
High
|
Low
| |
High
|
Low
| |
High
|
Low
| |
High
|
Low
| |
|---|
| |
n=21
|
n=81
|
p-value
|
n=57
|
n=45
|
p-value
|
n=18
|
n=84
|
p-value
|
n=50
|
n=52
|
p-value
|
n=9
|
n=93
|
p-value
|
|---|
|
Age ≥60
|
4 (19%)
|
23 (28%)
|
0.58
|
13 (23%)
|
14 (31%)
|
0.37
|
7 (39%)
|
20 (24%)
|
0.24
|
13 (26%)
|
14 (27%)
|
1
|
3 (33%)
|
24 (26%)
|
0.70
|
|
FIGO stage I
|
17 (81%)
|
65 (80%)
|
1
|
48 (84%)
|
34 (76%)
|
0.32
|
14 (78%)
|
68 (81%)
|
0.75
|
44 (88%)
|
38 (73%)
|
0.081
|
9 (100%)
|
73 (78%)
|
0.20
|
|
Pure histology
|
21 (100%)
|
78 (96%)
|
1
|
55 (96%)
|
44 (98%)
|
1
|
17 (94%)
|
82 (98%)
|
0.45
|
49 (98%)
|
50 (96%)
|
1
|
8 (89%)
|
91 (98%)
|
0.24
|
|
Positive peritoneal cytology
|
7 (33%)
|
24 (30%)
|
0.79
|
23 (40%)
|
8 (18%)
|
0.017
|
1 (6%)
|
30 (36%)
|
0.011
|
18 (36%)
|
13 (25%)
|
0.28
|
4 (44%)
|
27 (29%)
|
0.45
|
|
Endometriosis present
|
13 (62%)
|
45 (56%)
|
0.63
|
37 (65%)
|
21 (47%)
|
0.073
|
13 (72%)
|
45 (54%)
|
0.19
|
29 (58%)
|
29 (56%)
|
0.84
|
5 (56%)
|
53 (57%)
|
1
|
|
Residual tumor present
|
0 (0%)
|
2 (2%)
|
1
|
1 (2%)
|
1 (2%)
|
1
|
0 (0%)
|
2 (2%)
|
1
|
1 (2%)
|
1 (2%)
|
1
|
0 (0%)
|
2 (2%)
|
1
|
|
Lymphadenectmy undone
|
2 (10%)
|
13 (16%)
|
0.73
|
6 (11%)
|
9 (20%)
|
0.26
|
4 (22%)
|
11 (13%)
|
0.30
|
5 (10%)
|
10 (19%)
|
0.26
|
1 (11%)
|
14 (15%)
|
1
|
|
Adjuvant chemotherapy performed
|
19 (90%)
|
76 (94%)
|
0.63
|
53 (93%)
|
42 (93%)
|
1
|
17 (94%)
|
78 (93%)
|
1
|
47 (94%)
|
48 (92%)
|
1
|
8 (89%)
|
87 (94%)
|
0.49
|
- FIGO International Federation of Gynecology and Obstetrics
